Biotech Values

[DewDiligence]

the [Squalamine] eyedrop will be given twice a day.

Regardless of the route of administration and the dosing frequency, the fundamental problem with Squalamine is that it’s a relatively weak VEGF inhibitor. It was taken from nature “as is,” and was never subjected to the medicinal-chemistry optimizations that are typically done on a small-molecule drug.